Literature DB >> 31044626

The Expression of ILT4 in Myeloid Dendritic Cells in Patients with Hepatocellular Carcinoma.

Lili Wang1, Jing Fan1, Wei Ye1, Jianbo Han2, Yufeng Zhang2, Liang Zhao2, Jie Duan2, Dandan Yin1, Yongxiang Yi2.   

Abstract

Immunoglobulin-like transcript (ILT) 4 is an inhibitory immune receptor of the immunoglobulin superfamily, which could deliver inhibitory signals and induce immunosuppression. The significance of the expression of ILT4 in mDCs subsets in patients with hepatocellular carcinoma (HCC) remains unclear. In this study, the frequency of mDCs subsets in the peripheral blood of 121 patients with HCC and 103 normal controls, and in the tumor and tumor free liver tissues (TFL) of 43 HCC patients was analyzed by flow cytometry. Then, the expressions of ILT4 in mDCs subsets in the microenvironment of liver cancer were also analyzed. Results showed that the percentage of CD1c+ subset was dramatically decreased in peripheral blood mononuclear cells (PBMCs) of HCC patients compared with normal controls, and also significantly decreased in tumor tissue compared with the TFL. The decreased of CD1c+ subset in blood could be a diagnostic factor for HCC with the area under the receiver operating characteristic curve 0.975 (P < 0.01). The percentage of ILT4+CD1c+ subset was dramatically increased in tumor than that of TFL and blood. There were significant correlations between the percentage of ILT4+ in CD1c+ subset in tumor and that of in blood. The percentage of ILT4+CD1c+ subset in tumor tissue was strongly associated with the Edmondson-Steiner stage in HCC (P = 0.03). Furthermore, the capacity of ILT4+CD1c+ subset producing IFN-γ was lower than ILT4- CD1c subset in PBMC of HCC patients following Poly I:C stimulation. Taken together, the increased ILT4+CD1c+ subset in tumor tissue might play an important role in immune suppression for patients with HCC.

Entities:  

Keywords:  CD1c subset; ILT4; Myeloid dendritic cells; hepatocellular carcinoma

Year:  2019        PMID: 31044626     DOI: 10.1080/08820139.2019.1571507

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  4 in total

1.  Introduction.

Authors:  Jacques Robert
Journal:  Immunol Invest       Date:  2019-10       Impact factor: 3.657

Review 2.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

3.  New and effective method to develop primary hepatocytes from liver cancer patients.

Authors:  Jia-Yan Li; Li-Li Wang; Jing Fan; Du-Xian Liu; Jian-Bo Han; Yu-Feng Zhang; Dan-Dan Yin; Yong-Xiang Yi
Journal:  Exp Biol Med (Maywood)       Date:  2022-04-26

4.  Analysis of the expression and prognosis for leukocyte immunoglobulin-like receptor subfamily B in human liver cancer.

Authors:  Jing Fan; Lili Wang; Miao Chen; Jiakang Zhang; Jiayan Li; Fangnan Song; Aidong Gu; Dandan Yin; Yongxiang Yi
Journal:  World J Surg Oncol       Date:  2022-03-24       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.